

# **SNOG – NORTHERN LIGHTS NEUROSCIENCE SYMPOSIUM**

## **Redefining Low-Grade Glioma Management in the Era of Molecular Oncology**

**Thursday, 9 April 2026**

**12:00 – 13:00**

**Chaired by Benedikte Hasselbalch  
with a Panel of Experts**

### **12:00 – 12:03 Welcome & Introduction**

Setting the stage for a multidisciplinary exploration of glioma biology & care

**Benedikte Hasselbalch (DK)**

### **12:03 – 12:13 The Role of IDH Mutations in Diffuse Low-Grade Gliomas**

What's in a Grade? Understanding IDH mutations, grading and risk classification

**David Scheie (DK)**

### **12:13 – 12:18 Current LGG Treatment Practice**

Clinical decision making and available treatments

**Benedikte Hasselbalch (DK), Petter Brandal (NO)**

### **12:18 – 12:28 Changing the Treatment Paradigm in IDH-Mutant Low-Grade Glioma: The INDIGO Experience**

Efficacy, safety and role of vorasidenib in the future of LGG treatment

**Martin van den Bent (NL)**

### **12:28 – 12:57 Patient Cases**

How would you treat this patient?

**Martin van den Bent (NL), Petter Brandal (NO),  
Benedikte Hasselbalch (DK), Francesco Latini (SE), David Scheie (DK)**

### **12:57 – 13:00 Conclusion**

Final remarks and closing of the symposium

**Benedikte Hasselbalch (DK)**